Insider Trading July 13, 2026 07:07 AM

Genesco Director Gregory Sandfort Acquires $99,980 in Shares at Fair Value Threshold

Director's purchase aligns with InvestingPro's valuation model, coinciding with proxy advisory support and leadership transition.

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
GCO

Gregory A. Sandfort, a director at Genesco Inc. (NYSE:GCO), has increased his stake in the company through a recent purchase of 2,958 shares. The transaction, executed on July 9, 2026, valued at $33.80 per share, totals $99,980. This acquisition price matches InvestingPro’s Fair Value for the stock, suggesting the director views the current valuation as favorable. The purchase was made through Sandfort Investments III, LLC, bringing Sandfort’s indirect ownership to 29,172 shares. Genesco's stock has seen a 38% year-to-date gain and currently trades at $34.12, with a market capitalization of $379 million.

Genesco Director Gregory Sandfort Acquires $99,980 in Shares at Fair Value Threshold
GCO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director Gregory Sandfort purchased 2,958 shares at $33.80, aligning with InvestingPro's Fair Value model, indicating potential confidence in the stock's valuation.
  • Genesco has secured support from major proxy advisory firms for its board nominees, while facing challenges from an activist investor group holding 9.1% of the company.
  • The company is undergoing leadership changes, with Jonathan Collins set to succeed Mimi E. Vaughn as CFO, signaling strategic shifts in corporate governance.

Gregory A. Sandfort, a director at Genesco Inc. (NYSE:GCO), has increased his holdings in the company, according to a filing with the Securities and Exchange Commission. On July 9, 2026, Sandfort purchased 2,958 shares of common stock.

The shares were acquired at a price of $33.80 per share, totaling $99,980. Notably, this purchase price aligns precisely with InvestingPro’s Fair Value of $33.80, suggesting the director may see the current valuation as attractive. The stock has delivered strong returns with a year-to-date gain of 38% and currently trades at $34.12 with a market cap of $379 million. Following this transaction, Mr. Sandfort’s indirect ownership in Genesco common stock stands at 29,172 shares. The shares were acquired by Sandfort Investments III, LLC.

Investors seeking deeper insights can access comprehensive analysis through InvestingPro’s Pro Research Report, available for GCO and 1,400+ other US equities, which transforms complex data into actionable intelligence.

In other recent news, Genesco Inc. has received backing from three independent proxy advisory firms, including Glass Lewis & Co., Egan-Jones Proxy Services, and Institutional Shareholder Services (ISS), which recommended shareholders support the company’s nine director nominees at the upcoming annual meeting. ISS, in particular, advised shareholders to vote for all nominees, citing Genesco’s strong shareholder return and improved operating performance. Meanwhile, an activist investor group, the Radoff-Jumana Group, has challenged the qualifications of two board members and proposed replacing them with their own nominees, Westervelt T. Ballard, Jr. and Paula J. Poskon. This group, holding approximately 9.1% of Genesco, has urged shareholders to vote against directors Thurgood Marshall, Jr. and Joanna Barsh. Additionally, Genesco announced the appointment of Jonathan Collins as Senior Vice President, Finance and Chief Financial Officer, effective August 3, 2026. Collins will be taking over from Mimi E. Vaughn, who has been serving as Interim CFO since March. These developments highlight ongoing changes and strategic decisions within the company.

Key Points

  • Director Gregory Sandfort purchased 2,958 shares at $33.80, aligning with InvestingPro's Fair Value model, indicating potential confidence in the stock's valuation.
  • Genesco has secured support from major proxy advisory firms for its board nominees, while facing challenges from an activist investor group holding 9.1% of the company.
  • The company is undergoing leadership changes, with Jonathan Collins set to succeed Mimi E. Vaughn as CFO, signaling strategic shifts in corporate governance.

Risks and Uncertainties

  • The presence of an activist investor group challenging board qualifications introduces potential uncertainty regarding board stability and shareholder alignment.
  • Leadership transition from Interim CFO Mimi E. Vaughn to Jonathan Collins may impact operational continuity and financial reporting during the handover period.
  • Market volatility and the stock's recent 38% year-to-date gain could lead to short-term price fluctuations, affecting investor sentiment and valuation perceptions.

Risks

  • The presence of an activist investor group challenging board qualifications introduces potential uncertainty regarding board stability and shareholder alignment.
  • Leadership transition from Interim CFO Mimi E. Vaughn to Jonathan Collins may impact operational continuity and financial reporting during the handover period.
  • Market volatility and the stock's recent 38% year-to-date gain could lead to short-term price fluctuations, affecting investor sentiment and valuation perceptions.

More from Insider Trading

Anixa Biosciences CEO Purchases $15,200 in Shares Amid Clinical Milestones Jul 13, 2026 Iperionx CEO Arima Acquires $497,227 in Company Shares Amid Strategic Positioning Jul 13, 2026 IperionX Leadership Increases Stake Amid Market Volatility Jul 13, 2026 SharkNinja Director-Linked Entity Offloads $401M in Stock as Shares Near 52-Week Peak Jul 13, 2026 Caris Life Sciences Director Jon Halbert Executes $990K Insider Purchase Amid Strategic Expansion Jul 13, 2026